Articles

Emerald Health Pharmaceuticals is a science-based company.  Our team of scientists, along with researchers from collaborating organizations, have published many scientific articles in high-quality, peer-reviewed journals regarding our proprietary cannabinoid-derived therapies.

Multiple Sclerosis

Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy” Journal of Neuroinflammation (2018) 15:64 DOI 10.1186/s12974-018-1103-y Authors: Carmen Navarrete, Francisco Carrillo-Salinas, Belén Palomares, Miriam Mecha, Carla Jiménez-Jiménez, Leyre Mestre, Ana Feliú, Maria L. Bellido, Bernd L. Fiebich, Giovanni Appendino, Marco A. Calzado, Carmen Guaza and Eduardo Muñoz

A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis”. PLoS One (2014) 9(4): e94733, DOI: 10.1371/journal.pone.0094733. Authors: Francisco J. Carrillo-Salinas, Carmen Navarrete, Mirian Mecha M, Ana Feliú, Juan A. Collado, Irene Cantarero, Maria L. Bellido, Eduardo Muñoz and Carmen Guaza.

A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis”. Journal of Neuroimmune Pharmacology. (2012) 4:1002-1016, DOI: 10.1007/s11481-012-9399-3. Authors: Aitor G. Granja, Francisco Carrillo-Salinas, Alberto Pagani, María Gómez-Cañas, Roberto Negri, Carmen Navarrete, Miriam Mecha, Leyre Mestre, Bernd L. Fiebich, Irene Cantarero, Marco A. Calzado, Maria L. Bellido, Javier Fernandez-Ruiz, Giovanni Appendino, Carmen Guaza and Eduardo Muñoz.

Scleroderma

Cannabinoid derivatives acting as dual PPARγ/CB2 agonists as therapeutic agents for systemic sclerosis”. Biochemical Pharmacology (2019) 163:321-334 DOI: 10.1016/j.bcp.2019.02.029. Authors: Adela García-Martín, Martín Garrido-Rodríguez, Carmen Navarrete, Diego Caprioglio, Belén Palomares, Jim DeMesa, Alain Rolland, Giovanni Appendino, and Eduardo Muñoz

EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis”. Biochemical Pharmacology (2018) 157:304-313, DOI: 10.1016/j.bcp.2018.07.047. Authors: Adela García-Martín, M. Garrido-Rodríguez, Carmen Navarrete, Carmen Del Río C, Maria L. Bellido, Giovanni Appendino, Marco A. Calzado and Eduardo Muñoz.

The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways”. Scientific Report (2016) 6:21703, DOI. 10.1038/srep21703. Authors: Carmen del Río, Carmen Navarrete, Juan A.  Collado, M. Luz Bellido, María Gómez-Cañas, M. Ruth Pazos, Javier Fernández-Ruiz, Federica Pollastro, Giovanni Appendino, Marco A. Calzado, Irene Cantarero and Eduardo Muñoz.

Parkinson’s Disease

Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor” Journal of Neuroinflammation (2018) 15:19 DOI 10.1186/s12974-018-1060-5 Authors: Concepción García, María Gómez-Cañas, Sonia Burgaz, Belén Palomares, Yolanda Gómez-Gálvez, Cristina Palomo-Garo, Sara Campo, Joel Ferrer-Hernández, Carolina Pavicic, Carmen Navarrete, M. Luz Bellido, Moisés García-Arencibia, M. Ruth Pazos, Eduardo Muñoz and Javier Fernández-Ruiz

Development of An oral treatment with the PPAR-γ-acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson’s disease”. Molecules (2019) 24(15). pii: E2702, DOI: 10.3390/molecules24152702. Authors: Sonia Burgaz, Concepción García, Maria Gómez-Cañas, Eduardo Muñoz and Javier Fernández-Ruiz.

Huntington’s Disease

Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration” Translational Neurodegeneration (2019) 8:9 DOI:10.1186/s40035-019-0148-x Authors: José Aguareles, Juan Paraíso-Luna, Belén Palomares, Raquel Bajo-Grañeras, Carmen Navarrete, Andrea Ruiz-Calvo, Daniel García-Rincón, Elena García-Taboada, Manuel Guzmán, Eduardo Muñoz and Ismael Galve-Roperh